Abstract | INTRODUCTION: AIM: METHODS: Patients with advanced malignancy were entered at different treatment levels according to symptom severity. The dose was altered according to response (minimum dose 6.25 mg daily po, maximum 25 mg by 24-h subcutaneous infusion). Symptoms and side effects were recorded daily from 0 (baseline) to day 5 using a four-point scale. Any improvement in nausea/ vomiting score was taken as a response. RESULTS: Sixty-five patients were entered. The cause of nausea and vomiting was multifactorial in the majority of patients, 35/65 (54%). As expected in a study of patients with poor performance status, the attrition rate was high. Of 53 patients evaluable for response at day 2, 33 (62%) showed some improvement in nausea or vomiting. At day 5, improvement was seen in 20/34 (58%). There was no significant change in "side effects" from baseline with time. CONCLUSION:
|
Authors | A Kennett, J Hardy, S Shah, R A'Hern |
Journal | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
(Support Care Cancer)
Vol. 13
Issue 9
Pg. 715-21
(Sep 2005)
ISSN: 0941-4355 [Print] Germany |
PMID | 15700129
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Dopamine Antagonists
- Methotrimeprazine
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Dopamine Antagonists
(administration & dosage, adverse effects, therapeutic use)
- Dose-Response Relationship, Drug
- Female
- Humans
- Male
- Methotrimeprazine
(administration & dosage, adverse effects, therapeutic use)
- Middle Aged
- Nausea
(drug therapy)
- Neoplasms
(drug therapy)
- Treatment Outcome
- Vomiting
(drug therapy)
- Withholding Treatment
|